|
||||||
|
 | |
| |
| Differntial gene expression between RNA A-to-I edited tumor samples versus normal samples |
| |
| |
| The effects of the RNA editing to the stability of the RNA structures |
| |
| |
| |
| |
|
Editing gene: ERCC4 (CAeditome ID:2072) |
Gene summary for ERCC4 |
 Gene summary |
| Gene information | Gene symbol | ERCC4 | Gene ID | 2072 |
| Gene name | ERCC excision repair 4, endonuclease catalytic subunit | |
| Synonyms | ERCC11|FANCQ|RAD1|XFEPS|XPF | |
| Cytomap | 16p13.12 | |
| Type of gene | protein-coding | |
| Description | DNA repair endonuclease XPFDNA excision repair protein ERCC-4DNA repair protein complementing XP-F cellsexcision repair cross-complementation group 4excision repair cross-complementing rodent repair deficiency, complementation group 4excision-repair, | |
| Modification date | 20210531 | |
| UniProtAcc | Q92889 | |
| Context | - 33490679(The ECCR1 rs11615, ERCC4 rs2276466, XPC rs2228000 and XPC rs2228001 polymorphisms increase the cervical cancer risk and aggressiveness in the Bangladeshi population) |
| Gene ontology of each this gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Gene | GO ID | GO term | PubMed ID |
| ERCC4 | GO:0010521 | DNA repair endonuclease XPF | 18812185 |
| ERCC4 | GO:0051974 | DNA repair endonuclease XPF | 18812185 |
| ERCC4 | GO:0006289 | DNA repair endonuclease XPF | 10644440 |
| ERCC4 | GO:0003677 | DNA repair endonuclease XPF | 14734547 |
| ERCC4 | GO:0004520 | DNA repair endonuclease XPF | 8797827 |
| ERCC4 | GO:0003697 | DNA repair endonuclease XPF | 10413517 |
| ERCC4 | GO:0004520 | DNA repair endonuclease XPF | 10413517 |
| ERCC4 | GO:0004520 | DNA repair endonuclease XPF | 14734547 |
| ERCC4 | GO:0033683 | DNA repair endonuclease XPF | 10413517 |
| ERCC4 | GO:1904357 | DNA repair endonuclease XPF | 18812185 |
| ERCC4 | GO:1905768 | DNA repair endonuclease XPF | 18812185 |
| ERCC4 | GO:0000781 | DNA repair endonuclease XPF | 14690602 |
| ERCC4 | GO:0000781 | DNA repair endonuclease XPF | 14690602 |
| ERCC4 | GO:0005634 | DNA repair endonuclease XPF | 12571280 |
| ERCC4 | GO:0000109 | DNA repair endonuclease XPF | 10644440 |
| ERCC4 | GO:0000110 | DNA repair endonuclease XPF | 10413517 |
| ERCC4 | GO:0070522 | DNA repair endonuclease XPF | 14690602 |
| ERCC4 | GO:0070522 | DNA repair endonuclease XPF | 17055345 |
Top |
RNA A-to-I events for ERCC4 |
| RNA A-to-I editing events across TCGA 33 cancers data sets based on Ensembl gene isoform structure. |
 |
| RNA editing frequencies across 33 cancers of gene: ENSG00000175595.13 |
 |
| RNA A-to-I editing events in Cancer. |
| CAediting_1090018(13927304, +), CAediting_1090019(13936947, +), CAediting_1090020(13937039, +), CAediting_1090021(13937177, +), CAediting_1090022(13948558, +), CAediting_1090023(13948576, +), CAediting_1090024(13948579, +), CAediting_1090025(13948591, +), CAediting_1090026(13948592, +), CAediting_1090027(13948593, +), CAediting_1090028(13948596, +), CAediting_1090029(13948605, +), CAediting_1090030(13948617, +), CAediting_1090031(13948639, +), CAediting_1090032(13948645, +), CAediting_1090033(13948646, +), CAediting_1090034(13948652, +), CAediting_1090035(13948657, +), CAediting_1090036(13948662, +), CAediting_1090037(13948665, +), CAediting_1090038(13948676, +), CAediting_1090039(13948679, +), CAediting_1090040(13948680, +), CAediting_1090041(13948686, +), CAediting_1090042(13948691, +), CAediting_1090043(13948692, +), CAediting_1090044(13948711, +), CAediting_1090045(13948715, +), CAediting_1090046(13948721, +), CAediting_1090047(13948722, +), CAediting_1090048(13948727, +), CAediting_1090049(13948734, +), CAediting_1090050(13949343, +), CAediting_1090051(13949347, +), CAediting_1090052(13949352, +), CAediting_1090053(13949359, +), CAediting_1090054(13949386, +), CAediting_1090055(13950012, +), CAediting_1090056(13950017, +), CAediting_1090057(13950025, +), CAediting_1090058(13950061, +), CAediting_1090059(13950100, +), CAediting_1090060(13950148, +), CAediting_1090061(13950186, +), CAediting_1090062(13950200, +), |
Top |
RNA editing positional annotations for ERCC4 using Annovar |
| Protein coding RNA editing(s). |
| CAeditome ID | Position | Variant type | ENST | NTchange | AAchange | SIFT_score | Polyphen2_HVAR_score | PROVEAN_pred |
| Gene structure information of RNA editing(s). |
| CAeditome ID | Position | Variant type |
| CAediting_1090018 | chr16_13927304_+ | intronic |
| CAediting_1090019 | chr16_13936947_+ | ncRNA_intronic |
| CAediting_1090020 | chr16_13937039_+ | ncRNA_intronic |
| CAediting_1090021 | chr16_13937177_+ | ncRNA_intronic |
| CAediting_1090022 | chr16_13948558_+ | UTR3 |
| CAediting_1090023 | chr16_13948576_+ | UTR3 |
| CAediting_1090024 | chr16_13948579_+ | UTR3 |
| CAediting_1090025 | chr16_13948591_+ | UTR3 |
| CAediting_1090026 | chr16_13948592_+ | UTR3 |
| CAediting_1090027 | chr16_13948593_+ | UTR3 |
| CAediting_1090028 | chr16_13948596_+ | UTR3 |
| CAediting_1090029 | chr16_13948605_+ | UTR3 |
| CAediting_1090030 | chr16_13948617_+ | UTR3 |
| CAediting_1090031 | chr16_13948639_+ | UTR3 |
| CAediting_1090032 | chr16_13948645_+ | UTR3 |
| CAediting_1090033 | chr16_13948646_+ | UTR3 |
| CAediting_1090034 | chr16_13948652_+ | UTR3 |
| CAediting_1090035 | chr16_13948657_+ | UTR3 |
| CAediting_1090036 | chr16_13948662_+ | UTR3 |
| CAediting_1090037 | chr16_13948665_+ | UTR3 |
| CAediting_1090038 | chr16_13948676_+ | UTR3 |
| CAediting_1090039 | chr16_13948679_+ | UTR3 |
| CAediting_1090040 | chr16_13948680_+ | UTR3 |
| CAediting_1090041 | chr16_13948686_+ | UTR3 |
| CAediting_1090042 | chr16_13948691_+ | UTR3 |
| CAediting_1090043 | chr16_13948692_+ | UTR3 |
| CAediting_1090044 | chr16_13948711_+ | UTR3 |
| CAediting_1090045 | chr16_13948715_+ | UTR3 |
| CAediting_1090046 | chr16_13948721_+ | UTR3 |
| CAediting_1090047 | chr16_13948722_+ | UTR3 |
| CAediting_1090048 | chr16_13948727_+ | UTR3 |
| CAediting_1090049 | chr16_13948734_+ | UTR3 |
| CAediting_1090050 | chr16_13949343_+ | UTR3 |
| CAediting_1090051 | chr16_13949347_+ | UTR3 |
| CAediting_1090052 | chr16_13949352_+ | UTR3 |
| CAediting_1090053 | chr16_13949359_+ | UTR3 |
| CAediting_1090054 | chr16_13949386_+ | UTR3 |
| CAediting_1090055 | chr16_13950012_+ | UTR3 |
| CAediting_1090056 | chr16_13950017_+ | UTR3 |
| CAediting_1090057 | chr16_13950025_+ | UTR3 |
| CAediting_1090058 | chr16_13950061_+ | UTR3 |
| CAediting_1090059 | chr16_13950100_+ | UTR3 |
| CAediting_1090060 | chr16_13950148_+ | UTR3 |
| CAediting_1090061 | chr16_13950186_+ | UTR3 |
| CAediting_1090062 | chr16_13950200_+ | UTR3 |
| Repat-regional RNA editing(s). |
| CAeditome ID | Position | Repeat family | Repeat sub family | Repeat name |
| CAediting_1090018 | chr16_13927304_+ | SINE | Alu | AluSx |
| CAediting_1090019 | chr16_13936947_+ | SINE | Alu | AluJb |
| CAediting_1090020 | chr16_13937039_+ | SINE | Alu | AluJb |
| CAediting_1090021 | chr16_13937177_+ | SINE | Alu | AluJb |
| CAediting_1090050 | chr16_13949343_+ | SINE | Alu | AluSz6 |
| CAediting_1090051 | chr16_13949347_+ | SINE | Alu | AluSz6 |
| CAediting_1090052 | chr16_13949352_+ | SINE | Alu | AluSz6 |
| CAediting_1090053 | chr16_13949359_+ | SINE | Alu | AluSz6 |
| CAediting_1090054 | chr16_13949386_+ | SINE | Alu | AluSz6 |
| CAediting_1090055 | chr16_13950012_+ | SINE | Alu | AluSx |
| CAediting_1090056 | chr16_13950017_+ | SINE | Alu | AluSx |
| CAediting_1090057 | chr16_13950025_+ | SINE | Alu | AluSx |
| CAediting_1090058 | chr16_13950061_+ | SINE | Alu | AluSx |
| CAediting_1090059 | chr16_13950100_+ | SINE | Alu | AluSx |
| CAediting_1090060 | chr16_13950148_+ | SINE | Alu | AluSx |
| CAediting_1090061 | chr16_13950186_+ | SINE | Alu | AluSx |
| CAediting_1090062 | chr16_13950200_+ | SINE | Alu | AluSx |
Top |
RNA A-to-I editing events in the alternative splicing sites for ERCC4 |
| RNA A-to-I editing(s) in the alternative splicing sites. |
| AStype | CAeditomID | Editing position | AS position | AS direction | Exonic location | Wildtype sequence | Wildtype splicing strength | RNA edited sequence | RNA edited splicing strength |
| Differential percent of spliced in (PSI) between RNA A-to-I edited and non-edited samples for ENSG00000175595.13.ERCC4. |
| Correlation between RNA A-to-I editing and PSI for ENSG00000175595.13.ERCC4. |
Top |
Differntial gene expression between RNA A-to-I edited versus non-edited samples for ERCC4 |
| Differential gene expressions between RNA A-to-I edited and non-edited tumor samples. * The grey color means N/A. |
 | |
| Correlation between RNA A-to-I editing and gene expression. |
 | |
| - Differentially expressed gene between RNA A-to-I edited samples versus non-edited samples. * Click on the image to enlarge it in a new window. |
Top |
Protein coding region RNA A-to-I editings for ERCC4 |
| - Lollipop plot for RNA A-to-I editings across protein structure. * Click on the image to enlarge it in a new window. |
Top |
The effects of the RNA editing to the miRNA binding sites for ERCC4 |
| **If you are searching a miRNA gene with RNA editing events in its seed regions, please see the search pages of miRNA targets to discover the effects of this RNA editing event to miRNA regulations. For more information, please check the files in the Download page. |
| RNA A-to-I editing in the 3'-UTR regions of mRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in the 3'-UTR regions of mRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs lost binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to the 3'-UTR region of mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| CAediting_1351755 | chr19_40282625_- | ENSG00000175595.13 | ENST00000575156 | hsa-miR-641 | 13933213 | 13933219 | 7mer-1a | 13933193 | 13933219 | 144 | -23.93 |
| RNA A-to-I editing in miRNAs lost binding to the 3'-UTR mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| Differentially expressed gene-miRNA network |
Top |
The effects of the RNA editing to the stability of the RNA structures for ERCC4 |
| - RNA A-to-I editing in mRNA. * Click on the image to enlarge it in a new window. |
| ENST | ENST type | RNA structure without RNA A-to-I editing. | RNA structure with RNA A-to-I editing. |
| RNA A-to-I editing in RNA structures for Minimum free energy (MFE). |
| CAeditom_ID | ENST | Editing_Position | MFE_withoneAI | MFE_withoutAI | MFE_withmultipleAI |
Top |
Relation with ADAR for ERCC4 |
| Correlation between ADAR gene expression and RNA editing frequency |
| Cancer | CAeditomID | position | ADAR1 (p-val) | ADAR1 (coeff.) | ADAR2 (p-val) | ADAR2 (coeff.) | ADAR3 (p-val) | ADAR3 (coeff.) |
| BRCA | CAediting_1090022 | chr16_13948558_+ | 7.66487776145431e-09 | 0.308080113793209 | . | . | . | . |
| SKCM | CAediting_1090023 | chr16_13948576_+ | 2.26639056325675e-05 | 0.496190814557823 | . | . | . | . |
| HNSC | CAediting_1090023 | chr16_13948576_+ | 1.29495723787225e-06 | 0.574408752858207 | . | . | . | . |
| LUSC | CAediting_1090023 | chr16_13948576_+ | 0.00524589848727258 | 0.385231968012111 | . | . | . | . |
| BRCA | CAediting_1090023 | chr16_13948576_+ | 3.83462583729071e-20 | 0.492971938543607 | . | . | . | . |
| LGG | CAediting_1090023 | chr16_13948576_+ | 0.00729011479189209 | 0.229975630444926 | . | . | . | . |
| KIRC | CAediting_1090026 | chr16_13948592_+ | . | . | 1.06509807212216e-06 | 0.612989632820165 | . | . |
| LGG | CAediting_1090026 | chr16_13948592_+ | . | . | 0.0150190572437669 | 0.315235390019101 | . | . |
| BRCA | CAediting_1090026 | chr16_13948592_+ | 0.000999877829985981 | 0.233869107257438 | 0.0403907197096016 | 0.146931305876996 | . | . |
| BRCA | CAediting_1090027 | chr16_13948593_+ | 0.000601158665566326 | 0.255415182900966 | . | . | . | . |
| BRCA | CAediting_1090028 | chr16_13948596_+ | 5.98520954418863e-05 | 0.314644131266757 | . | . | . | . |
| BRCA | CAediting_1090037 | chr16_13948665_+ | 0.00163560894551254 | 0.32051723427096 | . | . | . | . |
| LGG | CAediting_1090038 | chr16_13948676_+ | 0.0101014733318014 | 0.286061226934409 | . | . | . | . |
| OV | CAediting_1090038 | chr16_13948676_+ | 0.0304152881504193 | 0.240708439793681 | . | . | . | . |
| BRCA | CAediting_1090038 | chr16_13948676_+ | 4.50604185560213e-07 | 0.328148808395757 | . | . | . | . |
| LGG | CAediting_1090040 | chr16_13948680_+ | 0.000802451870323749 | 0.358842905816252 | . | . | . | . |
| BRCA | CAediting_1090040 | chr16_13948680_+ | 3.40518131945085e-16 | 0.497989770980038 | . | . | . | . |
| OV | CAediting_1090040 | chr16_13948680_+ | 1.9055776849342e-05 | 0.448229988155601 | . | . | . | . |
| BRCA | CAediting_1090042 | chr16_13948691_+ | 2.47288764138849e-18 | 0.488681834191433 | . | . | . | . |
| LUSC | CAediting_1090042 | chr16_13948691_+ | 0.00444141159927773 | 0.388353882035371 | . | . | . | . |
| HNSC | CAediting_1090042 | chr16_13948691_+ | 0.00106954566568862 | 0.422226688828811 | . | . | . | . |
| OV | CAediting_1090042 | chr16_13948691_+ | 1.07490660770449e-06 | 0.503103488574 | . | . | . | . |
| LGG | CAediting_1090042 | chr16_13948691_+ | 5.77516395207018e-05 | 0.404540529226766 | . | . | . | . |
| HNSC | CAediting_1090043 | chr16_13948692_+ | . | . | 0.00169584602669556 | 0.406640448299344 | . | . |
| KIRC | CAediting_1090043 | chr16_13948692_+ | . | . | 0.00304863750035131 | 0.399408800841722 | . | . |
| SKCM | CAediting_1090043 | chr16_13948692_+ | . | . | 1.18079569422064e-06 | 0.592833083378478 | . | . |
| BRCA | CAediting_1090043 | chr16_13948692_+ | . | . | 0.000871321369814546 | 0.201455126537235 | . | . |
| BRCA | CAediting_1090053 | chr16_13949359_+ | 0.00647446497171282 | 0.172122545055615 | . | . | . | . |
Top |
Relation with cancer stages for ERCC4 |
| Correlation between Cancer stages and RNA editing frequency |
| Cancer | Stage_type | CAeditomID | position | P-val | Coeff. |
| BRCA | pathologic_stage | CAediting_1090028 | chr16_13948596_+ | 0.0485897409640096 | 0.161320546388231 |
| BRCA | pathologic_stage | CAediting_1090043 | chr16_13948692_+ | 0.012044556367185 | 0.154629029488154 |
Top |
Relation with survival for ERCC4 |
| Correlation between RNA editing and survival |
| Cancer | CAeditomID | position | KMpvalue | Coxpvalue | CoxHR |
Top |
RelatedDrugs for ERCC4 |
| Approved drugs targeting this gene. (DrugBank Version 5.1.8 2021-01-03) |
| Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ERCC4 |
| Diseases associated with this gene. (DisGeNet 7.0) |
| Gene | Disease ID | Disease name | # pubmeds | Source |
| ERCC4 | C0268140 | Xeroderma pigmentosum, group F | 10 | CLINGEN;CTD_human;GENOMICS_ENGLAND;UNIPROT |
| ERCC4 | C3808988 | FANCONI ANEMIA, COMPLEMENTATION GROUP Q | 5 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| ERCC4 | C1970416 | XFE Progeroid Syndrome | 3 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| ERCC4 | C0015625 | Fanconi Anemia | 2 | GENOMICS_ENGLAND;ORPHANET |
| ERCC4 | C1449862 | Micronuclei, Genotoxicant-Induced | 2 | CTD_human |
| ERCC4 | C1449861 | Micronuclei, Chromosome-Defective | 2 | CTD_human |
| ERCC4 | C0751852 | Arsenic Induced Polyneuropathy | 1 | CTD_human |
| ERCC4 | C0005684 | Malignant neoplasm of urinary bladder | 1 | CTD_human |
| ERCC4 | C0274862 | Nervous System, Organic Arsenic Poisoning | 1 | CTD_human |
| ERCC4 | C0311375 | Arsenic Poisoning | 1 | CTD_human |
| ERCC4 | C0740345 | Germ Cell Cancer | 1 | CTD_human |
| ERCC4 | C0751039 | Cockayne Syndrome, Type I | 1 | ORPHANET |
| ERCC4 | C0751364 | Cancer, Embryonal | 1 | CTD_human |
| ERCC4 | C0751365 | Cancer, Embryonal and Mixed | 1 | CTD_human |
| ERCC4 | C0751851 | Arsenic Encephalopathy | 1 | CTD_human |
| ERCC4 | C0274861 | Arsenic Poisoning, Inorganic | 1 | CTD_human |
| ERCC4 | C1720811 | Tumor of Rete Testis | 1 | CTD_human |
| ERCC4 | C3463824 | MYELODYSPLASTIC SYNDROME | 1 | GENOMICS_ENGLAND |
| ERCC4 | C4228778 | Abnormality of radial ray | 1 | GENOMICS_ENGLAND |
| ERCC4 | C4721453 | Peripheral Nervous System Diseases | 1 | CTD_human |
| ERCC4 | C0027654 | Embryonal Neoplasm | 1 | CTD_human |
| ERCC4 | C0005695 | Bladder Neoplasm | 1 | CTD_human |
| ERCC4 | C0023465 | Acute monocytic leukemia | 1 | GENOMICS_ENGLAND |
| ERCC4 | C0023467 | Leukemia, Myelocytic, Acute | 1 | GENOMICS_ENGLAND |
| ERCC4 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| ERCC4 | C0265219 | Miller Dieker syndrome | 1 | GENOMICS_ENGLAND |
| ERCC4 | C0027658 | Neoplasms, Germ Cell and Embryonal | 1 | CTD_human |
| ERCC4 | C0039590 | Testicular Neoplasms | 1 | CTD_human |
| ERCC4 | C0153594 | Malignant neoplasm of testis | 1 | CTD_human |
| ERCC4 | C0205851 | Germ cell tumor | 1 | CTD_human |
| ERCC4 | C0205852 | Neoplasms, Embryonal and Mixed | 1 | CTD_human |
